Q-omics provides the consensus-scored TDGF1P6 profile across patient tissues and cancer cell-line models. TDGF1P6 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TDGF1P6 is differentially expressed in 5, with the highest sampling consensus in KICH. Additionally, TDGF1P6 RNA expression shows 11,343 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, KICH, and THYM as cancer lineages where TDGF1P6 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TDGF1P6 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TDGF1P6 survival associations across molecular data types. TDGF1P6 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TDGF1P6 RNA expression–survival associations across cancer types. High TDGF1P6 expression shows unfavorable associations in MESO, UVM and KIRC, but favorable associations in HNSC, KIRP and LAML. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for TDGF1P6 RNA expression.
This table summarizes TDGF1P6 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in KICH for RNA.
This table ranks reproducible tumor–normal expression differences for TDGF1P6. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TDGF1P6 shows lower tumor expression in KICH, KIRP and THCA and higher tumor expression in LIHC and HNSC. The KICH box plot shows higher TDGF1P6 RNA expression in normal versus tumor tissue (log2 FC = −0.487, t-test p < 0.001).
This table shows molecular features associated with TDGF1P6 in patient tissues and cancer cell lines. In patient samples, TDGF1P6 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set.
